Across TCGA pan-cancer cohorts, ARL4C Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ARL4C data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARL4C Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARL4C expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

HNSC and BLCA are the cancer types where ARL4C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.133	0.625	.040	6	view →
BLCA	OS	Median	IV	0.509	0.284	.009	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: ARL4C tumor-vs-normal RNA expression · all ARL4C data types